CVRX

CVRX

CVRx Inc

Revenue grew 100% of years5Y
Hold

CVRx develops, manufactures, and commercializes neuromodulation devices for cardiovascular diseases. Its main product, Barostim, delivers electrical pulses to carotid artery baroreceptors, enhancing baroreflex activation therapy for improved heart function.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$136today

Score Overview

1 Year
Score
Net Growth2.51%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth8.01%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score6.7
Net Growth-20.64%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth369.38%
Rev TrendEvery year
Revenue Consistencyโ€”
All Time
Score
Net Growth-20.64%
Net Trend80%
Net Income Consistency
Rev Growth369.38%
Rev TrendEvery year
Revenue Consistency

See the full market ranking โ†’

CVRx Inc fundamental performance

Between 2021 and 2025, revenue grew from $ 13M to $ 56M and net income went from -$ 43M to -$ 53M. Revenue increased in 100% of the years measured; net income in 80%.

CVRx Inc currently holds a 5-year HDB Score of 6.7 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.73โ€”
1 Year2025-08-12
$ 7.51-63.65%
5 Years2021-08-12
$ 20.14-86.44%
All Time2021-06-30
$ 28.00-90.25%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 61M-$ 51M$ 64M
2025$ 56M-$ 53M$ 75M
2024$ 51M-$ 59M$ 105M
2023$ 39M-$ 41M$ 90M
2022$ 22M-$ 41M$ 106M
IPO2021$ 13M-$ 43M$ 142M

Explore beyond CVRX

You're looking at CVRx Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies